Investigational Drug Details
| Drug ID: | D474 |
| Drug Name: | Cilostazol |
| Synonyms: | Cilostazol; Cilostazole |
| Type: | Chemical drug |
| DrugBank ID: | DB01166 |
| DrugBank Description: | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. |
| PubChem ID: | -- |
| CasNo: | 73963-72-1 |
| Repositioning for NAFLD: | Yes |
| SMILES: | O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2 |
| Structure: |
|
| InChiKey: | RRGUKTPIGVIEKM-UHFFFAOYSA-N |
| Molecular Weight: | 369.4607 |
| DrugBank Targets: | cGMP-inhibited 3',5'-cyclic phosphodiesterase A inhibitor |
| DrugBank MoA: | Cilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation. |
| DrugBank Pharmacology: | Cilostazol reduces the symptoms of intermittent claudication, as indicated by an increased walking distance. Intermittent claudication is pain in the legs that occurs with walking and disappears with rest. The pain occurs due to reduced blood flow to the legs. |
| DrugBank Indication: | Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest). |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 on-going (NCT04761848) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0320 | NCT04761848 | Phase 1/Phase 2 | Recruiting | No Results Available | February 16, 2021 | February 22, 2022 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A08502 | 32083947 | Can J Physiol Pharmacol | Combined treatments with metformin and phosphodiesterase inhibitors alleviate nonalcoholic fatty liver disease in high-fat diet fed rats: a comparative study. | Details |
| A09070 | 31885103 | Fundam Clin Pharmacol | Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats. | Details |
| A12606 | 30366981 | Mol Pharmacol | Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK. | Details |
| A18559 | 27057275 | Oxid Med Cell Longev | Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis. | Details |
| A23636 | 23607402 | Hepatol Res | Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis. | Details |
| A27348 | 18596193 | Gut | Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. | Details |